Novo Nordisk warns sales could slide 13% as obesity competition mounts
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its drugs. … Read more









